fda safety communication semaglutide naion 2025 drug FDA warns Novo Nordisk for not reporting deadly side effects FDA Decisions Expected: October 2025

A 2023 analysis of semaglutide users with pre-existing bowel disorders found that 78% maintained or improved their IBS symptom scores after 12 weeks, provided they started at the lowest dose and titrated gradually

Since semaglutide typically produces weight loss in the 10-15% range, many users actually experience improved urinary health over time, even if they face some indirect risk during the initial adjustment period

Our Team Deep Financial Expertise Across Multiple Sectors Contact Us Scott E

Gutman made another career shift, committed to advancing glutathione research, eventually becoming both the personal physician of and trusted collaborator with Dr

In addition, some studies on recently marketed GLP-1 RAs such as dulaglutide (AWARD studies), albiglutide (HARMONY studies), and lixisenatide (GetGoal studies) included cardiovascular parameters as a part of their non-primary endpoints (Table 2)